BET inhibitors as a potential therapy for solitary fibrous tumor (SFT)
Official title: Bromodomain and extra-terminal motif (BET) inhibitors in Solitary fibrous tumor (SFT)
Funded at University of Texas Dallas · NIH-11527227 · Data updated 2026-11-12
Aimed at adults with solitary fibrous tumor, this grant explores BET inhibitors to block tumor-driving gene activity.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Texas Dallas NIH-funded |
| Lab location | 1 site (Richardson, United States) |
| Project start | April 1, 2024 |
| Project end | March 31, 2029 |
| Funding year | 2026 |
| Award (this year) | $141,522 |
| NIH project number | 3R01CA283330-03S1 |
| Project ID | NIH-11527227 on NIH RePORTER |
Who could benefit from this research
✓Could help
Adults with solitary fibrous tumor who may be considered for targeted therapies.
✕Less likely to help
Some patients may not respond to BET inhibitors or may experience treatment-related side effects.
What this research studies
Solitary fibrous tumor is a soft-tissue cancer linked to a NAB2-STAT6 gene fusion. The project investigates how BET inhibitors may interfere with the abnormal gene signaling driving SFT growth. Researchers plan to use CRISPR-based genome editing as part of the approach to understand tumor biology and test potential therapies. The study centers on translating laboratory findings toward options that could help patients with SFT, especially when surgery or radiation is challenging.
Why it matters
Potential benefit: If successful, BET inhibitors could become a new treatment option that slows tumor growth or improves outcomes for people with SFT.
How similar studies have gone: Past anti-angiogenic approaches in SFT have had limited success, making this a promising but exploratory step.
Where this research is happening
-
University of Texas Dallas
Richardson, United States Active
Researchers
- Principal investigator: Bleris, Leonidas — University of Texas Dallas
- Study coordinator: Bleris, Leonidas
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.